B-intervention	0	11	Accelerated
I-intervention	12	19	partial
I-intervention	20	26	breast
I-intervention	27	38	irradiation
O	39	44	using
O	45	54	intensity
O	54	55	-
O	55	64	modulated
O	65	77	radiotherapy
O	78	87	technique
O	88	96	compared
O	97	99	to
B-control	100	105	whole
I-control	106	112	breast
I-control	113	124	irradiation
O	125	128	for
O	129	137	patients
O	138	142	aged
O	143	145	70
O	146	151	years
O	152	154	or
O	155	160	older
O	160	161	:
O	162	170	subgroup
O	171	179	analysis
O	180	184	from
O	185	186	a
O	187	197	randomized
O	198	203	phase
O	204	205	3
O	206	211	trial
O	211	212	.

O	213	216	The
O	217	224	purpose
O	225	227	of
O	228	232	this
O	233	238	study
O	239	242	was
O	243	245	to
O	246	252	report
O	253	256	the
O	257	265	efficacy
O	266	269	and
O	270	273	the
O	274	280	safety
O	281	288	profile
O	289	291	on
O	292	295	the
O	296	302	subset
O	303	305	of
O	306	314	selected
O	315	320	early
O	321	327	breast
O	328	334	cancer
O	335	336	(
O	336	338	BC
O	338	339	)
O	340	348	patients
O	349	353	aged
O	354	356	70
O	357	362	years
O	363	365	or
O	366	371	older
O	372	376	from
O	377	378	a
O	379	385	single
O	385	386	-
O	386	392	center
O	393	398	phase
O	399	400	3
O	401	406	trial
O	407	416	comparing
O	417	422	whole
O	423	429	breast
O	430	441	irradiation
O	442	443	(
O	443	446	WBI
O	446	447	)
O	448	450	to
O	451	462	accelerated
O	463	470	partial
O	471	477	breast
O	478	489	irradiation
O	490	491	(
O	491	495	APBI
O	495	496	)
O	497	502	using
O	503	512	intensity
O	512	513	-
O	513	522	modulated
O	523	532	radiation
O	533	540	therapy
O	541	550	technique
O	550	551	.

O	552	559	Between
O	560	564	2005
O	565	568	and
O	569	573	2013
O	573	574	,
B-total-participants	575	578	520
O	579	587	patients
O	588	592	aged
B-age	593	597	more
I-age	598	602	than
I-age	603	605	40
I-age	606	611	years
O	612	615	old
O	616	620	were
O	621	629	enrolled
O	630	633	and
O	634	642	randomly
O	643	651	assigned
O	652	654	to
O	655	662	receive
O	663	669	either
O	670	673	WBI
O	674	676	or
O	677	681	APBI
O	682	684	in
O	685	686	a
O	687	688	1
O	688	689	:
O	689	690	1
O	691	696	ratio
O	696	697	.

O	698	706	Eligible
O	707	715	patients
O	716	720	were
B-eligibility	721	726	women
I-eligibility	727	731	with
I-eligibility	732	737	early
I-eligibility	738	740	BC
I-eligibility	741	742	(
I-eligibility	742	749	maximum
I-eligibility	750	758	diameter
I-eligibility	759	760	2
I-eligibility	760	761	.
I-eligibility	761	762	5
I-eligibility	763	765	cm
I-eligibility	765	766	)
I-eligibility	767	775	suitable
I-eligibility	776	779	for
I-eligibility	780	786	breast
I-eligibility	787	797	conserving
I-eligibility	798	805	surgery
O	805	806	.

O	807	811	This
O	812	817	study
O	818	820	is
O	821	831	registered
O	832	836	with
O	837	851	ClinicalTrials
O	851	852	.
O	852	855	gov
O	855	856	,
O	857	868	NCT02104895
O	868	869	.

O	870	871	A
O	872	877	total
O	878	880	of
B-total-participants	881	884	117
O	885	893	patients
B-age	894	898	aged
I-age	899	901	70
I-age	902	907	years
I-age	908	910	or
I-age	911	915	more
O	916	920	were
O	921	929	analyzed
O	930	931	(
B-control-participants	931	933	58
O	934	936	in
O	937	940	the
O	941	944	WBI
O	945	948	arm
O	948	949	,
B-intervention-participants	950	952	59
O	953	955	in
O	956	959	the
O	960	964	APBI
O	965	968	arm
O	968	969	)
O	969	970	.

O	971	973	At
O	974	975	a
O	976	982	median
O	983	989	follow
O	989	990	-
O	990	992	up
O	993	995	of
O	996	997	5
O	997	998	-
O	998	1003	years
O	1004	1005	(
O	1005	1010	range
O	1011	1012	3
O	1012	1013	.
O	1013	1014	4
O	1014	1015	-
O	1015	1016	7
O	1016	1017	.
O	1017	1018	0
O	1018	1019	)
O	1019	1020	,
O	1021	1024	the
B-outcome	1025	1036	ipsilateral
I-outcome	1037	1043	breast
I-outcome	1044	1049	tumor
I-outcome	1050	1060	recurrence
I-outcome	1061	1062	(
I-outcome	1062	1066	IBTR
I-outcome	1066	1067	)
I-outcome	1068	1072	rate
O	1073	1076	was
B-iv-bin-percent	1077	1078	1
I-iv-bin-percent	1078	1079	.
I-iv-bin-percent	1079	1080	9
I-iv-bin-percent	1081	1082	%
O	1083	1085	in
O	1086	1090	both
O	1091	1097	groups
O	1097	1098	.

O	1099	1101	No
O	1102	1113	significant
O	1114	1124	difference
O	1125	1132	between
O	1133	1136	the
O	1137	1140	two
O	1141	1147	groups
O	1148	1151	was
O	1152	1162	identified
O	1163	1164	(
O	1164	1167	log
O	1167	1168	-
O	1168	1172	rank
O	1173	1177	test
O	1178	1179	p
O	1180	1181	=
O	1182	1183	0
O	1183	1184	.
O	1184	1186	96
O	1186	1187	)
O	1187	1188	.

O	1189	1192	The
B-outcome	1193	1194	5
I-outcome	1194	1195	-
I-outcome	1195	1199	year
I-outcome	1200	1207	disease
I-outcome	1207	1208	-
I-outcome	1208	1212	free
I-outcome	1213	1221	survival
I-outcome	1222	1223	(
I-outcome	1223	1226	DFS
I-outcome	1226	1227	)
I-outcome	1228	1233	rates
O	1234	1236	in
O	1237	1240	the
O	1241	1244	WBI
O	1245	1250	group
O	1251	1254	and
O	1255	1259	APBI
O	1260	1265	group
O	1266	1270	were
B-cv-bin-percent	1271	1272	6
I-cv-bin-percent	1272	1273	.
I-cv-bin-percent	1273	1274	1
O	1275	1278	and
B-iv-bin-percent	1279	1280	1
I-iv-bin-percent	1280	1281	.
I-iv-bin-percent	1281	1282	9
I-iv-bin-percent	1283	1284	%
O	1284	1285	,
O	1286	1298	respectively
O	1299	1300	(
O	1300	1301	p
O	1302	1303	=
O	1304	1305	0
O	1305	1306	.
O	1306	1308	33
O	1308	1309	)
O	1309	1310	.

O	1311	1314	The
O	1315	1319	APBI
O	1320	1325	group
O	1326	1335	presented
O	1336	1349	significantly
O	1350	1356	better
O	1357	1364	results
O	1365	1367	in
O	1368	1373	terms
O	1374	1376	of
B-outcome	1377	1382	acute
I-outcome	1383	1387	skin
I-outcome	1388	1396	toxicity
O	1396	1397	,
O	1398	1409	considering
O	1410	1414	both
O	1415	1418	any
O	1419	1424	grade
O	1425	1426	(
O	1426	1427	p
O	1428	1429	=
O	1430	1431	0
O	1431	1432	.
O	1432	1436	0001
O	1436	1437	)
O	1438	1441	and
B-outcome	1442	1447	grade
I-outcome	1448	1449	2
I-outcome	1450	1452	or
I-outcome	1453	1459	higher
O	1460	1461	(
O	1461	1462	p
O	1463	1464	=
O	1465	1466	0
O	1466	1467	.
O	1467	1471	0001
O	1471	1472	)
O	1472	1473	.

O	1474	1477	Our
O	1478	1486	subgroup
O	1487	1495	analyses
O	1496	1502	showed
O	1503	1504	a
O	1505	1509	very
O	1510	1513	low
O	1514	1518	rate
O	1519	1522	and
O	1523	1525	no
O	1526	1537	significant
O	1538	1548	difference
O	1549	1551	in
O	1552	1557	terms
O	1558	1560	of
O	1561	1565	IBTR
O	1565	1566	,
O	1567	1572	using
O	1573	1577	both
O	1578	1581	WBI
O	1582	1585	and
O	1586	1590	APBI
O	1590	1591	.

O	1592	1593	A
O	1594	1605	significant
O	1606	1612	impact
O	1613	1615	on
O	1616	1624	patients
O	1625	1635	compliance
O	1636	1638	in
O	1639	1644	terms
O	1645	1647	of
O	1648	1653	acute
O	1654	1657	and
O	1658	1663	early
O	1664	1668	late
O	1669	1677	toxicity
O	1678	1681	was
O	1682	1687	shown
O	1687	1688	,
O	1689	1694	which
O	1695	1700	could
O	1701	1710	translate
O	1711	1713	in
O	1714	1715	a
O	1716	1726	consistent
O	1727	1738	improvement
O	1739	1741	of
O	1742	1749	overall
O	1750	1757	quality
O	1758	1760	of
O	1761	1765	life
O	1765	1766	.
